Companies / argenx
argenx Pipeline
Companyargenx is a global, commercial-stage biopharma company developing therapies for severe autoimmune diseases. Founded in 2008, it is headquartered in Amsterdam and listed on Nasdaq and Euronext Brussels under ARGX.
Continuously tracked·last revised
Data: CSV·JSON·Browse the trials
Follow argenx
Email me when this page changes — new trials, changes of phase or status, and results as they are posted.
No mail is going out yet — your address is recorded now, used for nothing else, and never shared.
Thanks — your request is recorded. No mail is sent yet.
That did not work. Check the address and try again.
Recruiting Phase 3
| Trial | Phase | Status | Sponsor | Started |
|---|---|---|---|---|
| A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease. NCT07596849 | Phase 3 | Recruiting | argenx | Started 2026-06 |
| A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease NCT07570316 | Phase 3 | Recruiting | argenx | Started 2026-06 |
| A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP NCT07091630 | Phase 3 | Recruiting | argenx | Started 2025-09 |
| A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP NCT06920004 | Phase 3 | Recruiting | argenx | Started 2025-08 |
| A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia NCT06544499 | Phase 3 | Recruiting | argenx | Started 2024-10 |
Recently started
Results recently posted
Pipeline
Phase by status
| Phase | Recruiting | Not yet | By invitation | Active | Completed | Terminated | Withdrawn | Available | Total |
|---|---|---|---|---|---|---|---|---|---|
| Phase 1 | 5 | — | — | 1 | 13 | — | — | — | 19 |
| Phase 2 | 4 | 4 | — | 5 | 9 | 3 | — | — | 25 |
| Phase 2/3 | 3 | 1 | 1 | — | 2 | — | — | — | 7 |
| Phase 3 | 5 | 1 | 1 | 5 | 9 | 4 | 1 | — | 26 |
| Phase 4 | 1 | — | — | — | 1 | — | — | — | 2 |
| Unknown | 6 | — | — | 1 | — | — | — | 1 | 8 |
Trials started per year
Conditions studied, by phase
| Condition | Phase 1 | Phase 2 | Phase 2/3 | Phase 3 | Phase 4 | Unknown | Total |
|---|---|---|---|---|---|---|---|
| Myasthenia Gravis | — | 3 | 3 | 7 | — | 4 | 17 |
| Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | — | 2 | 1 | 2 | 1 | 3 | 9 |
| Purpura, Thrombocytopenic, Idiopathic | — | 1 | 1 | 6 | — | — | 8 |
| Dermatomyositis | — | 1 | 1 | 1 | — | — | 3 |
| Myasthenic Syndromes, Congenital | 1 | — | — | 1 | — | 1 | 3 |
| Myositis | — | 1 | 1 | 1 | — | — | 3 |
| Pemphigus | — | 1 | — | 2 | — | — | 3 |
| Antisynthetase syndrome | — | — | 1 | 1 | — | — | 2 |
| Glomerulonephritis | — | 2 | — | — | — | — | 2 |
| Graves Disease | — | — | — | 2 | — | — | 2 |
Most active sponsors
| # | Sponsor | Trials | Phase 3 |
|---|---|---|---|
| 1 | argenx | 87 | 33 |
Frequent collaborators
| # | Collaborator | Trials |
|---|---|---|
| 1 | IQVIA Pty Ltd | 4 |
| 2 | Quintiles, Inc. | 2 |
| 3 | Zai Lab Pty. Ltd. | 1 |
| 4 | Zai Lab (Shanghai) Co., Ltd. | 1 |
Most studied interventions
| # | Intervention | Trials |
|---|---|---|
| 1 | efgartigimod alfa | 20 |
| 2 | Prednisone | 4 |
| 3 | Immunoglobulins, Intravenous | 3 |
| 4 | 23-valent pneumococcal capsular polysaccharide vaccine | 1 |
| 5 | ARGX-111 | 1 |
Terminations
Stated reasons
Reasons are grouped from the sponsor's own wording with a rule-based classifier; the original text is shown below.
Recently stopped
| Trial | Status | Stated reason | Stopped |
|---|---|---|---|
| NCT06441682 Terminated | Terminated | The study was terminated following review of interim data indicating that continuation was unlikely to demonstrate a clinically meaningful treatment effect. The decision was made to minimize unnecessary participant burden. | 2026-08-12 |
| NCT06307613 Terminated | Terminated | The pre-defined interim analysis concluded that continuing the trials is unlikely to demonstrate the intended efficacy. This decision is not related to safety concerns, and the safety profile of efgartigimod remains unchanged. | 2026-02-12 |
| NCT06307626 Terminated | Terminated | The pre-defined interim analysis concluded that continuing the trials is unlikely to demonstrate the intended efficacy. This decision is not related to safety concerns, and the safety profile of efgartigimod remains unchanged | 2026-02-12 |
| NCT05681481 Terminated | Terminated | Sponsor decision | 2025-03-20 |
| NCT05918978 Terminated | Terminated | Due to the phase 2 results of the main study (ARGX-113-2104) showing that efgartigimod-treated PC-POTS patients had no clinically meaningful improvement, the decision has been made to terminate this open-label extension study (ARGX-113-2105) study. | 2024-08-15 |
| NCT05810961 Terminated | Terminated | Sponsor decision | 2024-08-05 |
| NCT04598477 Terminated | Terminated | Based on the lack of observed efficacy in the primary study ARGX-113-1904, the sponsor decided to discontinue the open-label extension study. | 2024-03-25 |
| NCT04274452 Withdrawn | Withdrawn | The ARGX-113-1908 study will be replaced by a similar design with a subcutaneous formulation (ARGX-113-2004) | — |
Evidence
- Results reported
- 55.9%19 of 34 completed
- Published
- 2.9%1 of 34 completed
- Primary endpoint met
- 75%3 of 4 analyses
- Median months to report
- 12
Documents disclosed
Trial profile
- Median enrollment
- 74
- Median duration
- 33.2months
- Countries
- 60
- Study sites
- 3063
Who is enrolled
Median enrollment by phase
- Phase 1
- 52
- Phase 2
- 54
- Phase 2/3
- 12
- Phase 3
- 153
- Phase 4
- 27
- Unknown
- 200
Where trials run
Busiest cities
| # | City | Country | Trials |
|---|---|---|---|
| 1 | Barcelona | Spain | 32 |
| 2 | Milan | Italy | 30 |
| 3 | Katowice | Poland | 26 |
| 4 | Roma | Italy | 25 |
| 5 | Tbilisi | Georgia | 25 |
| 6 | Warsaw | Poland | 25 |
| 7 | Berlin | Germany | 24 |
| 8 | Madrid | Spain | 24 |
| 9 | Krakow | Poland | 23 |
| 10 | London | United Kingdom | 22 |